Belgium’s NeuVasQ Biotechnologies, a Université Libre de Bruxelles (ULB) spin-off developing pharmaceuticals to restore blood-brain barrier function, has named Emmanuel Lacroix chief executive and company director.
Dr Lacroix’ skills as an accomplished biotech executive are seen as complementary to the expertise of NeuVasQ founder and chief scientific officer Benoit Vanhollebeke.
Michel Allé, chairman of the board, said: “Emmanuel’s broad leadership experience in pharma and biotech – which includes accomplishments in venture capital, business development, strategy, and operations – will help NeuVasQ to realize its potential and propel this company on to the next stage.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze